Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).

• DOI: 10.1200/jco.2017.35.15_suppl.8511
• Publication Date: 2018-09-06T15:51:19Z
• Authors: Mark M. Awad; Giulia Costanza L...; Sasha Kravets; Suzanne Eleanor D...; Alexander E. Drilon; Sinead Noonan; D. Ross Camidge; Sai-Hong Ignatius Ou; Daniel Botelho Costa; Shirish M. Gadgeel; Conor Ernst Steuer; Patrick M. Forde; Viola Weijia Zhu; Yoko Korenaga Fukuda; Jeffrey W. Clark; Pasi A. Janne; Tony Mok; Lynette M. Sholl; Rebecca Suk Heist
• Keywords: Log-rank test

8511 Background: Dramatic responses to MET inhibitors have been reported in patients with NSCLC harboring activating mutations that cause exon 14 ( METdel14) skipping. We conducted a multicenter retrospective analysis of pts METdel14 determine if treatment impacts survival. Methods: collected clinicopathologic data on NSCLC. Event-time distributions were estimated using Kaplan-Meier and compared the log-rank test. Multivariable Cox models fitted estimate hazard ratios. Results: Of 148 mutant NSCLC, median age was 72 (range 43-88); 57% women, 41% never smokers. The most common histologies adenocarcinoma (77%) pulmonary sarcomatoid carcinoma (14%). Overlap oncogenic driver other genes rare. At time diagnosis, 70% had stage I-III disease, 30% IV disease. 34 metastastic disease who received inhibitor, overall survival (mOS) 8.1 months. In this cohort, cancers also concurrent amplification trend toward worse without (5.2 months vs 10.5 months, P = 0.06). 27 metastatic at least one inhibitor (including crizotinib, glesatinib, capmatinib, ABBV-399), mOS 24.6 A model adjusting for receipt as first- or second-line therapy time-dependent covariate demonstrated associated significant prolongation (HR 0.11, 95% CI 0.01-0.92, 0.04). Among 22 treated progression-free (PFS) 7.36 Conclusions: Forpts is an improvement prognosis appears be poor, particularly among amplification.